$23.72
1.62% yesterday
Nasdaq, Nov 15, 10:13 pm CET
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

BridgeBio Pharma Inc Target price 2024 - Analyst rating & recommendation

BridgeBio Pharma Inc Classifications & Recommendation:

Buy
88%
Hold
12%

BridgeBio Pharma Inc Price Target

Target Price $47.93
Price $23.72
Potential
Number of Estimates 14
14 Analysts have issued a price target BridgeBio Pharma Inc 2025 . The average BridgeBio Pharma Inc target price is $47.93. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 15 Analysts recommend BridgeBio Pharma Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the BridgeBio Pharma Inc stock has an average upside potential 2025 of . Most analysts recommend the BridgeBio Pharma Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 9.30 220.36
88.02% 2,269.43%
EBITDA Margin -6,375.81% -250.18%
972.37% 96.08%
Net Margin -8,026.99% -221.49%
911.67% 97.24%

14 Analysts have issued a sales forecast BridgeBio Pharma Inc 2024 . The average BridgeBio Pharma Inc sales estimate is

$220m
Unlock
. This is
1.19% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$248m 14.06%
Unlock
, the lowest is
$213m 2.19%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $9.3m 88.02%
2024
$220m 2,269.43%
Unlock
2025
$194m 12.10%
Unlock
2026
$433m 123.57%
Unlock
2027
$882m 103.66%
Unlock
2028
$1.6b 76.51%
Unlock

3 Analysts have issued an BridgeBio Pharma Inc EBITDA forecast 2024. The average BridgeBio Pharma Inc EBITDA estimate is

$-551m
Unlock
. This is
4.73% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-536m 1.82%
Unlock
, the lowest is
$-567m 7.66%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-593m 28.44%
2024
$-551m 7.03%
Unlock
2025
$-567m 2.78%
Unlock
2026
$-301m 46.79%
Unlock

EBITDA Margin

2023 -6,375.81% 972.37%
2024
-250.18% 96.08%
Unlock
2025
-292.55% 16.94%
Unlock
2026
-69.62% 76.20%
Unlock

8 BridgeBio Pharma Inc Analysts have issued a net profit forecast 2024. The average BridgeBio Pharma Inc net profit estimate is

$-488m
Unlock
. This is
7.16% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-444m 2.49%
Unlock
, the lowest is
$-512m 12.45%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-747m 21.17%
2024
$-488m 34.62%
Unlock
2025
$-697m 42.74%
Unlock
2026
$-629m 9.77%
Unlock
2027
$-321m 48.95%
Unlock
2028
$173m 153.83%
Unlock

Net Margin

2023 -8,026.99% 911.67%
2024
-221.49% 97.24%
Unlock
2025
-359.69% 62.40%
Unlock
2026
-145.16% 59.64%
Unlock
2027
-36.39% 74.93%
Unlock
2028
11.10% 130.50%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -3.95 -2.58
21.17% 34.68%
P/E negative
EV/Sales 26.40

8 Analysts have issued a BridgeBio Pharma Inc forecast for earnings per share. The average BridgeBio Pharma Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-2.58
Unlock
. This is
7.05% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.35 2.49%
Unlock
, the lowest is
$-2.71 12.45%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-3.95 21.17%
2024
$-2.58 34.68%
Unlock
2025
$-3.69 43.02%
Unlock
2026
$-3.33 9.76%
Unlock
2027
$-1.70 48.95%
Unlock
2028
$0.91 153.53%
Unlock

P/E ratio

Current -9.83 41.64%
2024
-9.18 6.61%
Unlock
2025
-6.43 29.96%
Unlock
2026
-7.13 10.89%
Unlock
2027
-13.97 95.93%
Unlock
2028
25.95 285.76%
Unlock

Based on analysts' sales estimates for 2024, the BridgeBio Pharma Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

26.40
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
20.34
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 26.72 95.73%
2024
26.40 1.18%
Unlock
2025
30.04 13.77%
Unlock
2026
13.44 55.27%
Unlock
2027
6.60 50.90%
Unlock
2028
3.74 43.35%
Unlock

P/S ratio

Current 20.59 95.88%
2024
20.34 1.17%
Unlock
2025
23.14 13.77%
Unlock
2026
10.35 55.27%
Unlock
2027
5.08 50.90%
Unlock
2028
2.88 43.35%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today